The Difference in Thyroid Stimulating Hormone Levels between Differentiated Carcinoma and Benign Enlargement

Area of Science:

• Endocrinology
• Oncology
• Head and Neck Surgery

Background:

• Papillary and follicular thyroid carcinoma are common head and neck cancers.
• Thyroid stimulating hormone (TSH) receptor is expressed in thyroid cancer and acts as a stimulant.
• TSH has diagnostic value in managing thyroid carcinoma.

Purpose of the Study:

• To determine the difference in TSH levels between differentiated thyroid carcinoma and benign thyroid enlargement.

Main Methods:

• A case-control study was conducted with 40 patients in each group (differentiated thyroid carcinoma and benign thyroid enlargement).
• TSH levels were measured before thyroidectomy.
• Exclusion criteria included pre-existing thyroid disorders, thyroid suppression therapy, and severe chronic diseases.

Main Results:

• Statistically significant differences in TSH levels were observed between differentiated thyroid carcinoma and benign thyroid enlargement groups (p = 0.001).
• The odds ratio for differentiated thyroid carcinoma was 8.42 (95% CI: 3.19-36.50).

Conclusions:

• Significant differences in TSH levels exist between differentiated thyroid carcinoma and benign thyroid enlargement.
• TSH levels may serve as a diagnostic marker in differentiating these conditions.